Stability of Myrmecia pilosula (Jack Jumper) Ant venom for use in immunotherapy

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 2, 2011, Pages 303-310

  Wiese, Michael D ^a,b   Davies, Noel W ^c   Chataway, Tim K ^d   Milne, Robert W ^a   Brown, Simon G A ^b,e   Heddle, Robert J ^d,f  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b ROYAL HOBART HOSPITAL   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

ELISA Inhibition; HPLC UV; Hymenoptera venom stability; Myrmecia pilosula; SDS PAGE Immunoblot

Indexed keywords

ALLERGEN; ANT VENOM; BENZYL ALCOHOL; GLYCEROL; PHOSPHATE; POLYSORBATE; SODIUM CHLORIDE; STABILIZING AGENT; SUCROSE;

ANT; ARTICLE; CONTROLLED STUDY; DRUG STABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOBLOTTING; IMMUNOTHERAPY; MYRMECIA PILOSULA; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHELF LIFE; STORAGE TEMPERATURE;

ANIMALS; ANT VENOMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DESENSITIZATION, IMMUNOLOGIC; DRUG STABILITY; DRUG STORAGE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREEZING; HYDROGEN-ION CONCENTRATION; HYPERSENSITIVITY; IMMUNOBLOTTING; IMMUNOTHERAPY; PEPTIDES; POLYSORBATES; TEMPERATURE; TIME FACTORS;

EID: 78650197630     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.08.024     Document Type: Article

References (31)

1. Brown S. Venom immunotherapy-an Australian perspective. Allergy Clin. Immunol. Int. 2005, 18:48-51.
2. Douglas R.G., Weiner J.M., Abramson M.J., O'Hehir R.E. Prevalence of severe ant-venom allergy in southeastern Australia. J. Allergy Clin. Immunol. 1998, 101:129-131.
3. Brown S.G., Franks R.W., Baldo B.A., Heddle R.J. Prevalence, severity, and natural history of jack jumper ant venom allergy in Tasmania. J. Allergy Clin. Immunol. 2003, 111:187-192.
4. Brown S.G, Wiese M.D., Blackman K.E., Heddle R.J. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003, 361:1001-1006.
5. Davies N.W., Wiese M.D., Brown S.G. Characterisation of major peptides in 'jack jumper' ant venom by mass spectrometry. Toxicon 2004, 43:173-183.
6. Wiese M.D., Chataway T.K., Davies N.W., Milne R.W., Brown S.G., Gai W.P., Heddle R.J. Proteomic analysis of Myrmecia pilosula (jack jumper) ant venom. Toxicon 2006, 47:208-217.
7. Wiese M.D., Brown S.G., Chataway T.K., Davies N.W., Milne R.W., Aulfrey S.J., Heddle R.J. Myrmecia pilosula (Jack Jumper) ant venom: identification of allergens and revised nomenclature. Allergy 2007, 62:437-443.
8. Donovan G.R., Street M.D., Tetaz T., Smith A.I., Alewood D., Alewood P., Sutherland S.K., Baldo B.A. Expression of jumper ant (Myrmecia pilosula) venom allergens: post-translational processing of allergen gene products. Biochem. Mol. Biol. Int. 1996, 39:877-885.
9. Bijli K.M., Singh B.P., Sridhara S., Gaur S.N., Arora N. Effect of various stabilizing agents on Imperata cylindrica grass pollen allergen extract. Clin. Exp. Allergy 2003, 33:65-71.
10. Sudha V.T., Srivastava D., Arora N., Gaur S.N., Singh B.P. Stability of protease-rich periplaneta Americana allergen extract during storage: formulating preservatives to enhance shelf life. J. Clin. Immunol. 2007, 27:294-301.
11. Nelson H.S., Ikle D., Buchmeier A. Studies of allergen extract stability: the effects of dilution and mixing. J. Allergy Clin. Immunol. 1996, 98:382-388.
12. Soldatova L.N., Paupore E.J., Burk S.H., Pastor R.W., Slater J.E. The stability of house dust mite allergens in glycerinated extracts. J. Allergy Clin. Immunol. 2000, 105:482-488.
13. Lockey R.F., Nicoara-Kasti G.L., Theodoropoulos D.S., Bukantz S.C. Systemic reactions and fatalities associated with allergen immunotherapy. Ann. Allergy Asthma Immunol. 2001, 87:47-55.
14. Aaronson D.W., Gandhi T.K. Incorrect allergy injections: allergists' experiences and recommendations for prevention. J. Allergy Clin. Immunol. 2004, 113:1117-1121.
15. Wiese M.D., Milne R.W., Davies N.W., Chataway T.K., Brown S.G., Heddle R.J. Myrmecia pilosula (Jack Jumper) ant venom: validation of a procedure to standardise an allergy vaccine. J. Pharm. Biomed. Anal. 2008, 46:58-65.
16. Niemeijer N.R., Meijer G., Kauffman H.F., De Monchy J.G. Determination of the stability of diluted allergen extracts using a concentration step prior to EAST inhibition. Clin. Exp. Allergy 1996, 26:953-956.
17. Donovan G.R., Street M.D., Baldo B.A., Alewood D., Alewood P., Sutherland S. Identification of an IgE-binding determinant of the major allergen Myr p I from the venom of the Australian jumper ant Myrmecia pilosula. Biochim. Biophys. Acta 1994, 1204:48-52.
18. Kettner A., Hughes G.J., Frutiger S., Astori M., Roggero M., Spertini F., Corradin G. Api m 6: a new bee venom allergen. J. Allergy Clin. Immunol. 2001, 107:914-920.
19. Winningham K.M., Fitch C.D., Schmidt M., Hoffman D.R. Hymenoptera venom protease allergens. J. Allergy Clin. Immunol. 2004, 114:928-933.
20. Note for Guidance on Allergen Products 1996, The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP), London, p. 6.
21. Wu Q.X., King M.A., Donovan G.R., Alewood D., Alewood P., Sawyer W.H., Baldo B.A. Cytotoxicity of pilosulin 1, a peptide from the venom of the jumper ant Myrmecia pilosula. Biochim. Biophys. Acta 1998, 1425:74-80.
22. Talbot J.C., Dufourcq J., de Bony J., Faucon J.F., Lussan C. Conformational change and self association of monomeric melittin. FEBS Lett. 1979, 102:191-193.
23. Ferreira Junior R.S., Sciani J.M., Marques-Porto R., Junior A.L., Orsi Rde O., Barraviera B., Pimenta D.C. Africanized honey bee (Apis mellifera) venom profiling: seasonal variation of melittin and phospholipase A(2) levels. Toxicon 2010, 56:355-362.
24. Hannan C.J., Stafford C.T., Rhoades R.B., Wray B.B., Baer H., Anderson M.C. Seasonal variation in antigens of the imported fire ant Solenopsis invicta. J. Allergy Clin. Immunol. 1986, 78:331-336.
25. Allergen Products (Ph Eur Monograph 1063) European Pharmacopoeia 2004, European Treaty Series 50, Strasbourg, pp. 79-80.
26. King T.P., Hoffman D., Lowenstein H., Marsh D.G., Platts-Mills T.A., Thomas W. Allergen nomenclature. Allergy 1995, 50:765-774.
27. Park J.W., Kim K.S., Jin H.S., Kim C.W., Kang D.B., Choi S.Y., Yong T.S., Oh S.H., Hong C.S. Der p 2 isoallergens have different allergenicity, and quantification with 2-site ELISA using monoclonal antibodies is influenced by the isoallergens. Clin. Exp. Allergy 2002, 32:1042-1047.
28. Reuter A., Luttkopf D., Vieths S. New frontiers in allergen standardization. Clin. Exp. Allergy 2009, 39:307-309.
29. Akdis M., Akdis C.A. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 2007, 119:780-791.
30. Asturias J.A., Ibarrola I., Arilla M.C., Vidal C., Ferrer A., Gamboa P.M., Vinuela J.E., Sanz M.L., Andreu C., Martinez A. Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen-specific immunotherapy. Clin. Exp. Allergy 2009, 39:1088-1098.
31. Aslam A., Kessler B., Batycka M., O'Callaghan C.A., Misbah S.A., Warrell D.A., Ogg G. Defining the T cell antigen proteome of wasp venom. Clin. Exp. Allergy 2006, 36:1274-1280.